As you rightfully state Edwards sales rely almost solely on one product . Acquiring AVR would give them the perfect opportunity to not only completely dominate the TAVR market but possibly see the end of the majority of SAVR operations . This would mean a reasonable uptick in TAVR sales as TAVR would become the normal way to replace Aortic valves . Edwards could possibly end up with a large array of products by utilising the ADAPT material . Personally I believe J@J and Abott Laboratories are going to buy into the bidding war here . Going to be interesting once the trials start . GLTATH
AVR Price at posting:
$23.50 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)